Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
about
Oncolytic virus therapy: A new era of cancer treatment at dawnAnti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma.Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.Oncolytic virus therapy for prostate cancer.Towards novel paradigms for cancer therapy.Exploiting human herpesvirus immune evasion for therapeutic gain: potential and pitfalls.Spontaneous and Engineered Compensatory HSV Mutants that Counteract the Host Antiviral PKR Response.Advance in herpes simplex viruses for cancer therapy.Current status of clinical trials assessing oncolytic virus therapy for urological cancers.Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.Monitoring adenoviral based gene delivery in rat glioma by molecular imaging.A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus."Armed" oncolytic herpes simplex viruses for brain tumor therapy.PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses.A third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice.
P2860
Q26739714-84EC8260-EEE3-4469-A39D-784540509D0BQ33579396-960DBA06-3DC9-4491-BF69-C7A605369581Q33894449-EB6BA064-3B5C-4926-B670-C69357D0B16EQ33995471-9980389C-1DE7-48DA-B9BA-FE4DFBAD4F6FQ35699072-15FF1202-42A9-4FFC-A000-A1B2A331FBDAQ37615535-0A386EF8-405B-4F40-84B9-A9CD2781DC9FQ37799251-9CB67047-0466-49D5-9A5C-C24D16017BDCQ37837495-118E7B97-6103-4FC3-878D-8FAF4E52C381Q37945174-605CD2C7-89B4-41D9-BE39-E5A67C4A7C09Q38096940-1B6B0F7A-4451-499C-929B-2C1898CDE7EBQ38741837-C60ABEB0-C1F4-4ED6-B469-B402094EF27AQ39745964-AA051E1D-4318-4363-BC0E-9B993BA9C578Q40585840-AFA6FF9E-EF54-47C4-8206-AF9E18449ED6Q40867510-0B8D44A3-1867-41E3-BD75-5F7D381223EEQ43189897-764AFAEC-AF0B-4D65-AA72-189A53EFE9F1Q45885668-E160D322-7BFC-429B-8B50-DE41014315A3Q47559554-9E847D00-F350-4B10-B6EA-D9EE8643B78E
P2860
Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Oncolytic herpes simplex virus ...... human prostate adenocarcinoma.
@en
type
label
Oncolytic herpes simplex virus ...... human prostate adenocarcinoma.
@en
prefLabel
Oncolytic herpes simplex virus ...... human prostate adenocarcinoma.
@en
P2093
P921
P1476
Oncolytic herpes simplex virus ...... human prostate adenocarcinoma.
@en
P2093
Hiroshi Fukuhara
Tomoki Todo
Yoshikazu Ito
P304
P356
10.1158/1078-0432.CCR-05-1090
P407
P577
2005-11-01T00:00:00Z